news
An aerial view shows the brine pools and processing areas of the Soquimich (SQM) lithium mine on the Atacama salt flat in the Atacama desert of northern Chile, January 10, 2013.REUTERS/Ivan Alvarado

Latham & Watkins and Zhong Lun Law Firm have advised Tianqi Lithium Corporation on its $1.7 billion secondary listing in Hong Kong, with Clifford Chance and JunHe advising the joint sponsors. The IPO is Hong Kong’s largest so far in 2022.

Established in 1995, the Chengdu-headquartered, Shenzhen-listed Tianqi Lithium is a producer of lithium chemicals for electric vehicle batteries. The listing forms part of the ‘newest fundraising rush’ of Chinese firms involved in electrical automobile battery and materials productions as the country looks to boost its domestic production of these commodities, Bloomberg reported.

The CC team was led by partners Fang Liu and Xiang Tianning, while the Latham team was led by partners Howard Lam, Cathy Yeung, and Terris Tang.

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

Latham, Milbank, SyCip act on largest greenfield infra FDI deal in Philippines

by Nimitt Dixit |

Milbank and SyCip Salazar Hernandez & Gatmaitan have acted for global investor Actis on its strategic partnership with the Philippines’ Meralco and its subsidiary, Solar Philippines New Energy Corporation, advised by Latham & Watkins, to invest $600 million in the Terra Solar Project.

Deals

SAM, CAM, Latham act on Ather Energy’s upcoming $536 mln IPO

by Nimitt Dixit |

Shardul Amarchand Mangaldas & Co is advising Indian electric two-wheeler maker Ather Energy on its upcoming $536.2 million initial public offering (45 billion rupees), as more emerging companies than ever before turn to India’s red-hot stock market to raise funds.

Deals

Trilegal, Latham, Quillon act on Platinum Equity’s India PE debut

by Nimitt Dixit |

Trilegal and Latham & Watkins have advised U.S.-based buyout fund Platinum Equity on its debut private equity deal in India, in the form of the acquisition of a majority stake in Inventia Healthcare, a Mumbai-based pharmaceutical company, at a valuation of $300 million.